Based on this YouTube video's total view count of 426K views and industry-standard rates, the estimated total earning is $299 - $854 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

Explore Pfizer new antiviral with 426,822 views, 10,800 likes, and 5,637 comments. Experience the impact of this video content that has captured audience attention.

Protectors from hospitalisation, the story so far. Oral meds than can be prescribed from home with onset of symptoms Molnupiravir, approved by MHRA https://www.gov.uk/government/news/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhra The antiviral was found to be safe and effective following a stringent review of the available evidence. https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/ Public domain data, Merck press release $ 700 per 5-day course Under 50% reduction in deuteriation Effect of early treatment with fluvoxamine Together Trial group Public domain data, Peer reviewed trial in the Lancet https://clinicaltrials.gov/ct2/show/NCT04727424 https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00448-4/fulltext Adults with a risk factor $4 for a 10-day course 32% protection against hospitalization 32% protection against death Fluvoxamine is approved by the Food and Drug Administration as an antidepressant Doctors already can prescribe it off-label — using their clinical judgment https://www.washingtonpost.com/science/2021/10/28/antidepressant-fluvoxamine-coronavirus-lancet/? https://bnf.nice.org.uk/drug/fluvoxamine-maleate.html https://www.togethertrial.com Ivermectin, Together trial results not yet released PFIZER’S NOVEL COVID-19 ORAL ANTIVIRAL TREATMENT CANDIDATE REDUCED RISK OF HOSPITALIZATION OR DEATH BY 89% IN INTERIM ANALYSIS OF PHASE 2/3 EPIC-HR STUDY https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate Public domain data, Pfizer press release PAXLOVID™ (PF-07321332; ritonavir) Found to reduce the risk of hospitalization or death by 89% Compared to placebo in non-hospitalized high-risk adults with COVID-19 Through Day 28 PAXLOVID group No deaths Placebo group 10 deaths Pfizer plans to submit the data as part of its ongoing rolling submission to the U.S. FDA for Emergency Use Authorization (EUA) as soon as possible Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) Randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness Scheduled interim analysis 89% reduction in risk of COVID-19-related hospitalization or death from any cause compared to placebo In patients treated within 3 days of symptom onset PAXLOVID group 0.8% of patients hospitalized 3/389 hospitalized with no deaths Placebo group 7.0% of patients hospitalized or died 27/385 hospitalized with 7 subsequent deaths (p less than 0.0001) 1 in 10,000 chance In patients treated within 5 days of symptom onset PAXLOVID group 1.0% of patients hospitalized 6/607 hospitalized with no deaths Placebo group 6. 7% of patients hospitalized or died 41/612 hospitalized, with 10 subsequent deaths p less than 0.0001 At the recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration (FDA), Pfizer will cease further enrollment into the study due to the overwhelming efficacy demonstrated in these results About the Phase 2/3 EPIC-HR Study Interim Analysis 1,219 adults enrolled out of 3,000 planned North and South America, Europe, Africa, and Asia Enrolled individuals had a laboratory-confirmed diagnosis of SARS-CoV-2 infection Mild to moderate symptoms At least one characteristic or underlying medical condition Randomized (1:1) to receive PAXLOVID™ or placebo orally every 12 hours for five days About the Phase 2/3 EPIC-HR Study Safety Data Safety data, n = 1881 Treatment-emergent adverse events PAXLOVID™group 19% Placebo group 21% Most of which were mild in intensity Fewer serious adverse events PAXLOVID™group 1.7% Placebo group 6.6% Discontinuation of study drug due to adverse events PAXLOVID™group 2.1% Placebo group 4.1% Pharmacology Specifically designed SARS-CoV-2-3CL protease inhibitor, an enzyme that the coronavirus needs to replicate Co-administration with a low dose of ritonavir helps slow the metabolism of PF-07321332 PF-07321332 inhibits viral replication at a stage known as proteolysis, which occurs before viral RNA replication In preclinical studies, PF-07321332 did not demonstrate evidence of mutagenic DNA interactions. EPIC-SR includes a cohort of vaccinated patients who have an acute breakthrough symptomatic COVID-19 infection and who have risk factors for severe illness.

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.